Physician profile
Frank Tobin
NPI 1275546533
$12,094.09
in general payments reported to CMS, 2019-2025
43 companies · $1,862 in 2025
The $1,862 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,866 · 2020: $1,486 · 2021: $1,979 · 2022: $1,963 · 2023: $1,657 · 2024: $1,282 · 2025: $1,862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,800.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,876.33 | 2019-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $1,380.92 | 2019-2025 | |
| Janssen Biotech, INC. | $1,100.80 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Sun Pharmaceutical Industries INC. | $702.65 | 2019-2025 | Winlevi, Ilumya |
| Regeneron Healthcare Solutions, INC. | $692.77 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $557.97 | 2019-2025 | |
| Ucb, INC. | $512.62 | 2019-2025 | Bimzelx |
| Leo Pharma INC. | $504.52 | 2019-2025 | Adbry, Anzupgo |
| Incyte Corporation | $504.13 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $466.59 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $460.61 | 2019-2025 | |
| Journey Medical Corporation | $424.15 | 2019-2021 | |
| Galderma Laboratories, L.P. | $395.30 | 2019-2025 | Nemluvio, Aklief |
| Amgen INC. | $326.20 | 2020-2025 | Otezla, Enbrel, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $265.55 | 2019-2025 | Jublia |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Tobin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.